INCB032304 is an important pharmaceutical intermediate. It can be used in the preparation of Ruxolitinib phosphate (I008849), a janus kinase inhibitor, and in the preparation of Barretinib.
More Information Supplier Page
INCB032304 is an important pharmaceutical intermediate. It can be used in the preparation of Ruxolitinib phosphate (I008849), a janus kinase inhibitor, and in the preparation of Barretinib.
More Information Supplier Page
KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2.
More Information Supplier PageKU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2.
More Information Supplier PageKU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2.
More Information Supplier PageKU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2.
More Information Supplier Page
Bortezomib (PS-341) is a potent 20S proteasome inhibitor (Ki: 0.6 nM, in a cell-free assay).
More Information Supplier Page
Bortezomib (PS-341) is a potent 20S proteasome inhibitor (Ki: 0.6 nM, in a cell-free assay).
More Information Supplier Page 
Ramatroban (BAY u3405) is a thromboxane A(2) (TxA(2)) antagonist marketed for allergic rhinitis. It has been used in trials studying the treatment of Asthma.
More Information Supplier Page
Ramatroban (BAY u3405) is a thromboxane A(2) (TxA(2)) antagonist marketed for allergic rhinitis. It has been used in trials studying the treatment of Asthma.
More Information Supplier Page 
